FAKTOR OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - BOERSE MUENCHEN 19:25:15 25/06/2024 BST | ||
| 1.96 EUR | +2.62% |
|
| Current month | -25.19% | ||
| 1 month | -21.29% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 25/06/24 | 1.96 | +2.62% |
| 24/06/24 | 1.91 | -8.61% |
| 21/06/24 | 2.09 | +3.47% |
| 20/06/24 | 2.02 | -4.72% |
| 19/06/24 | 2.12 | +3.41% |
Real-time BOERSE MUENCHEN
Last update June 25, 2024 at 07:25 pm
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GG2ECA |
| ISIN | DE000GG2ECA9 |
| Date issued | 11/01/2024 |
| Strike | 569.9 $ |
| Maturity | Unlimited |
| Parity | 46.39 : 1 |
| Emission price | 4.14 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.64 € |
|---|---|
| Lowest since issue | 1.73 € |
| Spread | 0.03 € |
| Spread % | 1.52% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.8
USD
Average target price
465.5
USD
Spread / Average Target
-1.75%
- Stock Market
- Certificates
- Certificat
